Knight Lends a Hand to a New Debt Fund
MONTREAL, CANADA–(Marketwired – Jul 9, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has invested in the Bloom Burton Healthcare Lending Trust (the “Trust”) managed by Stratigis Capital Advisors Inc. Knight subscribed for $500,000 Trust units as part of a $15.9 million private placement. The Trust […]
Knight Amplifies Its Innovative Product Sourcing Strategy
MONTREAL, QUEBEC–(Marketwired – Jul 7, 2015) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries, (“Knight”) announced today that it has expanded its innovative pharmaceutical product sourcing strategy by entering into an agreement with TVM Capital Life Science to invest USD$1.6 million into TVM Life Sciences Venture VII (“TVM Fund”), a fund dedicated […]
Knight Finding NEMO: The Sequel
MONTREAL, CANADA–(Marketwired – Jul 2, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into an agreement with Sectoral Asset Management Inc. (“Sectoral”) to reinvest US$10 million into its New Emerging Medical Opportunities Fund III, Ltd. (“NEMO III”) life science fund. Knight’s investment in NEMO […]
Knight Creates Synergy With Sale of Neuragen(R) U.S.
MONTREAL, CANADA–(Marketwired – Jun 26, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into a sale agreement with Synergy Strips Corp (OTCQB:SNYR) (“Synergy”) related to the U.S. rights to Neuragen®, an innovative OTC product that helps relieve pain caused by diabetic […]
Knight Extends Secured Loan
MONTREAL, CANADA–(Marketwired – Jun 26, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it has extended a secured loan of $800,000 to Extenway Solutions Inc. (TSX:EY) (“Extenway”), an innovative provider of technology solutions for the healthcare industry. The secured loan of $800,000, which matures […]
Chivalrous Knight Does Pro Bono
MONTREAL, QUEBEC–(Marketwired – Jun 26, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it has (1) extended a secured loan of US$15 million to Pro Bono Bio PLC (“Pro Bono Bio”), the world’s leading healthcare nanotechnology company, and (2) entered into an exclusive distribution […]
Finding NEMO Yields Financial Return For Knight
MONTREAL, QUEBEC–(Marketwired – Jun 8, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it has received a distribution of US$13.6 million related to its investment in Sectoral Asset Management Inc.’s (“Sectoral”) New Emerging Medical Opportunities Funds II, Ltd. (“NEMO II”) as part of a […]
Knight Secures Canadian Products in Two Separate Transactions
MONTREAL, CANADA–(Marketwired – Jun 4, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced the closing of two product transactions. 1. Knight secures its first Canadian product with modest existing sales Today, Knight acquired the assets related to Neuragen®, an innovative OTC product that helps relieve pain […]
Knight Therapeutics Inc. Announces Election of Directors
MONTREAL, QUEBEC–(Marketwired – Jun 4, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”) announced today that each director nominee listed in the Management Information Circular dated May 1, 2015 was elected as Director of the Company during the Annual Meeting of the Shareholders held in Montréal, Québec. The details of the election are […]
Knight to Present at Both the Jefferies Healthcare Conference in New York City and the National Bank Financial Quebec Conference in Toronto
MONTREAL, CANADA–(Marketwired – May 27, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, President & CEO, is scheduled to present a corporate update at the Jefferies Healthcare Conference on Monday, June 1, 2015 at 4:30 pm ET at the Grand Hyatt […]
